Therapeutics News and Research

RSS

Potential new treatment approach for schizophrenia

A new study reports important evidence for a potential new treatment approach for those diagnosed with schizophrenia.

25 Sep 2007

Adnexus Therapeutics to become a subsidiary of Bristol-Myers Squibb

Bristol-Myers Squibb and Adnexus Therapeutics have announced the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins.

25 Sep 2007

MIT model could improve some drugs' effectiveness

MIT researchers have developed a computer modeling approach that could improve a class of drugs based on antibodies, molecules key to the immune system.

24 Sep 2007

Heat shock proteins are co-opted for cancer

A Jekyll-Hyde mechanism that both protects healthy cells and enables cancer cells could be the basis for new cancer-fighting drugs.

21 Sep 2007

Heat shock proteins are co-opted for cancer

A Jekyll-Hyde mechanism that both protects healthy cells and enables cancer cells could be the basis for new cancer-fighting drugs.

20 Sep 2007

Spinal Muscular Atrophy Foundation and BG Medicine collaborate

The Spinal Muscular Atrophy Foundation and BG Medicine have announced a collaboration to discover plasma biomarkers of drug efficacy for spinal muscular atrophy (SMA), the leading genetic cause of mortality in infants and toddlers.

18 Sep 2007

Researchers genetically engineering microorganisms, such as E. coli, into tiny, cellular factories

Microorganisms may soon be efficiently and inexpensively producing novel pharmaceutical compounds, such as flavonoids, that fight aging, cancer or obesity, as well as high-value chemicals, as the result of research being conducted by University at Buffalo researchers.

18 Sep 2007

Oxford Genome Sciences partners with Medarex

Oxford Genome Sciences (UK) Ltd (OGeS) has announced a second partnering agreement with Medarex, Inc.

18 Sep 2007

Helix BioPharma awarded U.S. patent for adjunct chemotherapy applications

Helix BioPharma Corp. has announced the issuance of its second DOS47 patent (U.S. Patent # 7,264,800) from the United States Patent & Trademark Office, describing a method and composition for combining targeted DOS47 therapeutics with weakly basic chemotherapeutic drugs in adjunct treatment applications.

18 Sep 2007

GlaxoSmithKline to pursue novel antibacterial research program for DOD

GlaxoSmithKline has announced that it has signed an agreement with the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD), to identify and develop a new class of antibacterials targeting both Gram negative biothreats and conventional Gram negative hospital pathogens.

18 Sep 2007

Gene profiling can single out the worst cases of multiple myeloma and guide therapy

Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potentially guide therapy in the future.

18 Sep 2007

Virus experts step closer to treatment for hepatitis C

Nine hundred of the world's hepatitis C experts are meeting in Glasgow this week to discuss the latest research into the disease at the 14th International Symposium on Hepatitis C Virus and Related Viruses.

13 Sep 2007

Insight into the role of cancer stem cells in cancer initiation, progression and metastasis

Scientists have identified a distinct subpopulation of cancer stem cells (CSCs) that is responsible for metastasis of a deadly human pancreatic cancer.

13 Sep 2007

New insights into the complexity of HIV/AIDS

Three related papers published in the Sept. 1 edition of The Journal of Immunology provide key new insights into the complexity of HIV/AIDS. Don Sodora, Ph.D., a principal investigator in SBRI's Viral Vaccines Program who recently joined SBRI from the University of Texas, Southwestern Medical Center, is senior author on one of three papers that collectively show CD4 T-cell depletion, a critical symptom of AIDS, is likely a part of a multifaceted scenario that triggers disease rather than the only cause.

10 Sep 2007

Oncolytics Biotech issued new U.S. patent

Oncolytics Biotech Inc. has announced that it has been granted U.S. Patent 7,264,798 entitled "Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus."

5 Sep 2007

Detailed picture of prevalence of ADHD in U.S.

Most children in the United States who meet the medically accepted definition of Attention Deficit Hyperactivity Disorder (ADHD) have not been diagnosed by a physician, and are not consistently treated with medications, according to the first national ADHD prevalence study in children based on the "gold standard" of diagnostic criteria, according to a new study conducted by researchers at Cincinnati Children's Hospital Medical Center.

4 Sep 2007

Hamburg to become Europe's hub of drug discovery

Hamburg is on its way to becoming a leading hub of Europe's academic drug discovery, with the northern German city's town hall today announcing the foundation of European ScreeningPort GmbH, a company that will run a state-of-the-art drug discovery service centre.

4 Sep 2007

University of Utah receives $19.2 Million for HIV research

University of Utah biochemist Wesley I. Sundquist, Ph.D., has been awarded a five-year, $19.2 million National Institutes of Health (NIH) grant to establish an HIV research center to study the structural biology of the AIDS-causing virus.

3 Sep 2007

Discovery of novel cause of iron overload in patients with thalassemia

According to the study, thalassemia patients overproduce a protein called GDF15, which suppresses the production of a liver protein, hepcidin, which in turn leads to an increase in the uptake of dietary iron in the gut.

30 Aug 2007

Avicena signs distribution agreement with RITA Corporation for dermaceutical compounds

Avicena Group, Inc., a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases as well as dermaceutical products announced today that it has signed an exclusive worldwide distribution agreement with RITA Corporation, a leading supplier of specialty chemicals to the personal care industry.

29 Aug 2007